Attached files

file filename
EX-99.1 - BIOMIMETIC THERAPEUTICS, INC.exhibit99-1topline.htm

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported):  October 16, 2009 (October 13, 2009)

 

BIOMIMETIC THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

000-51934

62-1786244

(State or other jurisdiction of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

 

389 Nichol Mill Lane, Franklin, Tennessee 37067

(Address of principal executive offices)

 

(615) 844-1280

(Registrant's telephone number, including area code)

 

Not Applicable

(Former name, former address and former fiscal year,

if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

‪[  ]        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 

‪[  ]        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

‪[  ]        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 

‪[  ]        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 8.01.  Other Events.

On October 13, 2009, BioMimetic Therapeutics, Inc. issued a press release that announced positive top-line results from its North American pivotal (Phase III) randomized controlled trial comparing its fully synthetic, off-the-shelf bone growth factor product, Augment Bone Graft (“Augment”), to autograft  for use in hindfoot and ankle fusion surgery.  A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits

(d)  Exhibits

99.1 Press Release dated October 13, 2009.

 

 

 


SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

BIOMIMETIC THERAPEUTICS, INC.

 

 

By:             /s/ Earl Douglas                          

Name:  Earl Douglas

Title:    General Counsel           

 

Date:   October 16, 2009